The Alpha Execution Doctrine: Why Targeted Alpha Therapy Is Not a Molecule Problem
Alpha programmes rarely fail because the targeting vector misses. They fail earlier, in the industrial system built around the isotope. This report treats targeted alpha therapy as an execution problem rather than a clinical one, and shows why the five principal emitters are not interchangeable members of one modality.
What this report answers
- Why do targeted alpha therapy programmes stall at infrastructure rather than at efficacy?
- What does it cost a programme to defer its physics-critical hires until after Phase II?
- Why can a facility built for Lutetium-177 fail to host an alpha emitter at all?
- Which alpha emitters can be manufactured centrally, and which force production onto the clinical site?
- How do pharmaceutical sterility rules and nuclear containment rules conflict in the same room?
- What should a board ask before underwriting an alpha-stage asset?
$36M-$72M
ProGen Search's estimate of the direct capital erosion an 18-month infrastructure stall imposes on an alpha programme, which is the arithmetic the report uses to argue against deferring physics-critical hires.
0.15%
the level of trace isotopic contamination the report identifies as sufficient to change how a programme's clinical waste must be classified - a threshold well below what most programmes treat as material.
What the analysis establishes
The Beta Fallacy
The report names the assumption it is arguing against: that infrastructure, regulation and clinical workflow built for beta-emitting radioligand therapy extend linearly to alpha emitters. It establishes why the same physical properties that give alpha particles their therapeutic potency are the properties that disqualify standard pharmaceutical infrastructure, and treats emitter equivalence as a capital allocation error rather than a technical nuance.
Physics as the binding constraint
Each emitter is worked through from its governing physics outward: half-life, recoil energy, daughter decay products and terminal emissions. The report traces how each of those propagates into supply chain topology, facility engineering, waste classification and clinical workflow, and sets out where the chain from physics to infrastructure to timeline to capital most often breaks.
Execution fracture scenarios
Three composite scenarios illustrate recurring failure modes: a waste-classification dispute that halts site activation, a shielding load that a contracted facility cannot structurally carry, and a synchronisation breakdown on a short half-life production cycle. Each is presented with its cost, its delay, and the specific capability whose absence allowed it.
Where regulators disagree with each other
A separate section addresses a constraint that applies across the emitter family: the airflow conflict between pharmaceutical sterility requirements and nuclear containment requirements when a decay chain generates noble gases. The report explains why standard filtration does not resolve it and what class of engineering judgement does, without prescribing a single facility design.
Comparative emitter profiles and the cost of hiring late
The five principal emitters are profiled across a fixed causal chain - half-life, industrial model, core constraint, primary failure mode, critical early hire - so the profiles can be read against each other. A closing section quantifies what deferring those hires does to overhead, timeline and first-mover position, and puts an eight-question readiness test in front of boards.
How it was built
An industrial systems analysis rather than a clinical or market review. It reasons from published isotope physics and the regulatory frameworks governing radioactive materials, then works forward into facility engineering, logistics and organisational design. The scenarios are labelled by the report itself as composite illustrations, synthesised from recurring sector patterns rather than drawn from named organisations or events. Cost and timeline ranges are ProGen Search estimates, stated as ranges and attributed as such.
Written for boards and institutional investors underwriting alpha-stage assets, radiopharmaceutical developers planning facility and organisational design, and CDMOs and isotope suppliers assessing whether their existing infrastructure can carry alpha work.
Contents
- The Illusion of Emitter Equivalence
- Centralised Scarcity: The Recoil Constraint and Long-Tail Liability
- Execution Fracture Scenarios
- The Regional Architectural Challenge and the Gamma Tax
- The Hyperlocal Tether and the Synchronisation Constraint
- The Dual-Oversight Deadlock and the HVAC Collision
- The Dosimetry Tax and Hospital Workflow Economics
- Comparative Emitter Analysis: Industrial Profiles
- The Cost of Hiring Late
- Board Diagnostic: The Alpha Readiness Test
Regulators and frameworks referenced
FDA, NRC
The full 11-page briefing is free. Tell us where to send it and it downloads immediately.
The State of Radiopharmaceuticals 2026
This briefing works one layer down, at the physics and facility level. The flagship report takes the whole sector: named operators, capacity, capital flows and where the commercial positions actually sit.
See the full report →